Bacillus coagulans için Irritable Bowel Syndrome (IBS)
B Kanıt Bunu büyük ölçüde tutarlı sonuçlarla en az bir randomize çalışma desteklemektedir.Reduces abdominal pain, bloating, and diarrhea in IBS. Spore-forming nature provides excellent stability and gastric acid survival.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbacillus\u002Dcoagulans\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
Sonuç
Reduces abdominal pain, bloating, and diarrhea in IBS. Spore-forming nature provides excellent stability and gastric acid survival.
Key Study Findings
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
Etki: None
None
Popülasyon: patients with IBS from 32 RCTs evaluating 10 probiotic strains
Randomized Controlled Trial
n=61
4 weeks
Double-blind
Effects of a Bacillus subtilis HU58 and Heyndrickxia faecalis SC208 spore-forming probiotic formula on gastrointestinal …
Dose: None
vs: Placebo
Outcome: Abdominal pain (NRS) and stool consistency (BSFS)
Etki: None
P = 0.003 (pain); P = 0.035 (s
Popülasyon: Adults with diarrhoea-predominant IBS (IBS-D)
Randomized Controlled Trial
n=100
12 weeks
Role of Bacillus coagulans (Heyndrickxia coagulans)BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, …
Dose: None
vs: Control
Outcome: Pain outcomes
Etki: None
P < .001
Popülasyon: IBS patients
Meta-Analysis
Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review …
Dose: Various probiotic strains/mixtures
vs: Placebo
Outcome: Outcome-specific efficacy ranking in IBS
Etki: None
None
Popülasyon: Adults with IBS (RCTs)
Randomized Controlled Trial
12 weeks
Double-blind
The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in …
Dose: 20.5%
vs: placebo
Outcome: IBS symptom improvement
Etki: None
p = 0.038
Popülasyon: Adults with IBS
Review
Oral microbial shift induced by probiotic Bacillus coagualans along with its clinical perspectives.
Dose: None
vs: None
Outcome: colitis/IBD severity
Etki: None
None
Popülasyon: None
Key Statistics
3
Çalışmalar
400
Katılımcılar
↑
Positive
B
Derece
Referenced Papers
Journal of clinical …
2026
Beneficial microbes
2026
Medicine
2024
6 atıf
Nutrients
2023
33 atıf
Oral microbial shift induced by probiotic Bacillus coagualans along with its clinical perspectives.
Review
Journal of oral …
2023
12 atıf
International journal of …
2023
9 atıf
Journal of clinical …
2023
9 atıf
Medicine
2021
45 atıf
Journal of dietary …
2021
33 atıf
European journal of …
2020
20 atıf
Scientific reports
2019
65 atıf
Beneficial microbes
2019
45 atıf
Beneficial microbes
2019
29 atıf
Food & nutrition …
2018
162 atıf
Beneficial microbes
2018
59 atıf
Nutrition journal
2016
102 atıf
European review for …
2014
33 atıf
Gastroenterology and hepatology …
2014
Postgraduate medicine
2009
144 atıf
Methods and findings …
2009
104 atıf
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Yaygın Kullanılan Dozajlar
- general:
- 1-2 billion CFU/day
- ibssupport:
- 2 billion CFU/day (GBI-30 6086 strain)
Üst sınır: Well-tolerated up to 6 billion CFU/day in clinical trials
Araştırmalarda İncelenen Dozajlar
| Dozaj | Süre | Etki | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | 4 weeks | Positive | 61 |
| None | 12 weeks | Positive | 100 |
| Various probiotic strains/mixtures | -- | Positive | -- |
| 20.5% | 12 weeks | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
En iyi alım zamanı: With meals for optimal spore germination and colonization
Safety & Side Effects
Bildirilen Yan Etkiler
- ⚠ Mild gas during initial use (generally less than other probiotics due to spore form)
- ⚠ Occasional bloating
- ⚠ Rare loose stools
Bilinen Etkileşimler
- ● Antibiotics (spore form is more resistant than vegetative probiotics, but spacing still recommended)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
Tolere edilebilir üst alım: Well-tolerated up to 6 billion CFU/day in clinical trials
Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.
Frequently Asked Questions
Does Bacillus coagulans help with Irritable Bowel Syndrome (IBS)?
Based on 3 studies with 400 participants, there is moderate evidence from clinical studies that Bacillus coagulans may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Bacillus coagulans should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-2 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bacillus coagulans?
Reported side effects may include Mild gas during initial use (generally less than other probiotics due to spore form), Occasional bloating, Rare loose stools. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bacillus coagulans and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.
Related Evidence
Şu durum için diğer içerikler: Irritable Bowel Syndrome (IBS)
References
- [1] Roman Maslennikov et al.. J Clin Med. 2026. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. doi:10.3390/jcm15031152 PubMed
- [2] K Sorensen et al.. Benef Microbes. 2026. Effects of a Bacillus subtilis HU58 and Heyndrickxia faecalis SC208 spore-forming probiotic formula on gastrointestinal health: results of a randomised, … doi:10.1163/18762891-bja00113 PubMed
- [3] Sohel S Shaikh et al.. Medicine (Baltimore). 2024. Role of Bacillus coagulans (Heyndrickxia coagulans)BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, placebo-controlled clinical trial. doi:10.1097/MD.0000000000039134 PubMed
- [4] Peiwei Xie et al.. Nutrients. 2023. Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. doi:10.3390/nu15173856 PubMed
- [5] Aysha Jebin A et al.. J Oral Biol Craniofac Res. 2023. Oral microbial shift induced by probiotic Bacillus coagualans along with its clinical perspectives. doi:10.1016/j.jobcr.2023.03.013 PubMed
- [6] Ludovic D Langlois et al.. Int J Mol Sci. 2023. Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability in a Chronic-Restraint Stress Model. doi:10.3390/ijms24087220 PubMed
- [7] Barbara Skrzydło-Radomańska et al.. J Clin Med. 2023. The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel … doi:10.3390/jcm12144838 PubMed
- [8] Anil Kumar Gupta et al.. Medicine (Baltimore). 2021. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT … doi:10.1097/MD.0000000000023641 PubMed
- [9] Chiranjit Maity et al.. J Diet Suppl. 2021. Impact of a Gastrointestinal Stable Probiotic Supplement Bacillus coagulans LBSC on Human Gut Microbiome Modulation. doi:10.1080/19390211.2020.1814931 PubMed
- [10] Khadijeh Abhari et al.. Eur J Nutr. 2020. Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management? doi:10.1007/s00394-019-02060-y PubMed
- [11] Ratna Sudha Madempudi et al.. Sci Rep. 2019. Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel … doi:10.1038/s41598-019-48554-x PubMed
- [12] Y Mu et al.. Benef Microbes. 2019. Bacillus coagulans and its applications in medicine. doi:10.3920/BM2019.0016 PubMed
- [13] Y Mu et al.. Benef Microbes. 2019. Bacillus coagulans and its applications in medicine. doi:10.3920/BM2018.0016 PubMed
- [14] Muhammed Majeed et al.. Food Nutr Res. 2018. Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, … doi:10.29219/fnr.v62.1218 PubMed
- [15] M Ratna Sudha et al.. Benef Microbes. 2018. Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled … doi:10.3920/BM2017.0129 PubMed
- [16] Muhammed Majeed et al.. Nutr J. 2016. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled … doi:10.1186/s12937-016-0140-6 PubMed
- [17] R Urgesi et al.. Eur Rev Med Pharmacol Sci. 2014. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients … PubMed
- [18] Mehran Rogha et al.. Gastroenterol Hepatol Bed Bench. 2014. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. PubMed
- [19] Larysa Hun. Postgrad Med. 2009. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. doi:10.3810/pgm.2009.03.1984 PubMed
- [20] B J Dolin. Methods Find Exp Clin Pharmacol. 2009. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. doi:10.1358/mf.2009.31.10.1441078 PubMed
FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.